Get the latest news, insights, and market updates on IMUX (Immunic, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Immunic to present at healthcare investor conferences in March
Immunic Inc (NASDAQ:IMUX), a late-stage biotechnology company developing oral treatments for neurological and gastrointestinal diseases, will participate in two investor conferences this month. Chief executive Daniel Vitt and president Jason Tardio will take part in a fireside chat at the... Mar 3, 2026 - $IMUX
Immunic to Participate in Investor Conferences in March
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March: Mar 3, 2026 - $IMUX
Immunic secures $400M to support late-stage MS trials - ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week outlined how a newly secured up to $400 million private placement is set to support completion of late-stage trials and prepare the company for a potential commercial launch of vidofludimus calcium in multiple sclerosis. Speaking to Proactive, CEO... Feb 28, 2026 - $IMUX
Immunic sets stage for phase 3 MS data readout after $400M financing
Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage development, with key data expected by the end of 2026. The biotechnology company’s oral candidate,... Feb 26, 2026 - $IMUX
Immunic: Q4 Earnings Snapshot
The New York-based company said it had a loss of 12 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. Feb 26, 2026 - $IMUX
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update. Feb 26, 2026 - $IMUX
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at... Feb 17, 2026 - $IMUX
Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously disclosed private placement financing. Feb 17, 2026 - $IMUX
A Look At Immunic (IMUX) Valuation After Oversubscribed Funding And Leadership Changes
Immunic (IMUX) has moved into the spotlight after an oversubscribed private placement of up to US$400 million, paired with a CEO transition plan and board reshuffle related to its multiple sclerosis programs. See our latest analysis for Immunic. Investors appear to be reacting to the funding and leadership reset, with a 30 day share price return of 47.7% and a year to date share price return of 56.5%. However, the 1 year total shareholder return is still an 8.8% decline and the 5 year total... Feb 16, 2026 - $IMUX
Why Immunic (IMUX) Is Up 47.2% After $400 Million MS Push And Leadership Shake-Up
In February 2026, Immunic, Inc. announced an oversubscribed private placement of pre-funded and common warrants expected to raise up to US$400,000,000, alongside plans to complete late-stage multiple sclerosis trials, initiate a new phase 3 program in primary progressive multiple sclerosis, and prepare for potential commercialization of vidofludimus calcium. At the same time, the company outlined a leadership reshaping, elevating Simona Skerjanec to interim Chairperson, launching a search... Feb 15, 2026 - $IMUX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple